Casodex (Bicalutamide) - Summary

CASODEX SUMMARY

CASODEX®
(bicalutamide)
TABLETS

CASODEX^® (bicalutamide) Tablets for oral administration contain 50 mg of bicalutamide, a non-steroidal antiandrogen with no other known endocrine activity. The chemical name is propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-). The structural and empirical formulas are:

CASODEX is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D₂ metastatic carcinoma of the prostate.

CASODEX NEWS HIGHLIGHTS

Media Articles Related to Casodex (Bicalutamide)

Height Linked To Risk Of Prostate Cancer Development And Progression
Source: Cancer / Oncology News From Medical News Today [2008.09.04]

Too Much Calcium In Blood May Increase Risk Of Fatal Prostate Cancer
Source: Clinical Trials / Drug Trials News From Medical News Today [2008.09.04]

Study Links Serum Calcium, Prostate Cancer Death
Source: MedicineNet Cancer Specialty [2008.09.04]

ProsCan For Men: Randomised Controlled Trial Of A Decision Support Intervention For Men With Localised Prostate Cancer
Source: Cancer / Oncology News From Medical News Today [2008.09.03]

Scientists Find Second Site For Prostate Cancer Gene
Source: Genetics News From Medical News Today [2008.09.03]

more>>

Published Studies Related to Casodex (Bicalutamide)

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. [2007.10]

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. [2007]

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. [2007]

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. [2006.09]

Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. [2006.07]

more>>

Clinical Trials Related to Casodex (Bicalutamide)

Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX [Completed]

Casodex - Nolvadex Combination [Completed]

Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer [No longer available]

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer [Active, not recruiting]

Phase II Trial: Higher Dose Casodex in Hormone Refractory Prostate Cancer Patients. [Recruiting]

more>>